POLYMYXIN B

Generic Name/API: polymyxin b sulfate

Manufacturer: Fresenius Kabi

Dosage Forms & Strength & Pack Size:
Sterile Vials, 500,000 units per vial, 10 vials

Storage:
Before Reconstitution: Store at room temperature 68°F to 77°F (20°C to 25°C). Protect from light.

After Reconstitution: Product must be stored under refrigeration, between 2°C to 8°C,  and any unused portion should be discarded after 72 hours.

  • INDICATION
  • IMPORTANT SAFETY INFORMATION

Uses for Polymyxin B

Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa.

Polymyxin B (polymyxin b sulfate) sulfate is a drug of choice in the treatment of infections of the urinary tractmeninges, and bloodstream caused by susceptible strains of Ps. aeruginosa. It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa.

It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H influenzae, specifically meningeal infections. Escherichia coli, specifically urinary tract infections. Aerobacter aerogenes, specifically bacteremiaKlebsiella pneumoniae, specifically bacteremia.

NOTE: IN MENINGEAL INFECTIONS, POLYMYX-IN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B (polymyxin b sulfate) and other antibacterial drugs, polymyxin B (polymyxin b sulfate) should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Precautions for Polymyxin B

General. Prescribing polymyxin B (polymyxin b sulfate) in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

See WARNING box.

Baseline renal function should be done prior to therapy, with frequent monitoring of renal function and blood levels of the drug during parenteral therapy.

Avoid concurrent use of a curariform muscle relaxant and other neurotoxic drugs (ether, tubocurarine, succinylcholine, gallamine, decamethonium and sodium citrate) which may precipitate respiratory depression. If signs of respiratory paralysis appear, respiration should be assisted as required, and the drug discontinued.

As with other antibiotics, use of this drug may result in overgrowth of nonsusceptible organisms, including fungi.

If superinfection occurs, appropriate therapy should be instituted.

Contraindications for Polymyxin B

This drug is contraindicated in persons with a prior history of hypersensitivity reactions to polymyxins.

Scroll to Top